Quest Pharmatech, Inc.

Momenta Pharmaceuticals, Inc.

Altarex Medical Corp.

University of California

Altarex Corp.

Oncoquest Inc.

Birgit Corinna Schultes

Carlos J Bosques

Takashi Kei Kishimoto

Antoine A Noujaim

Ragupathy Madiyalakan

Christopher F Nicodemus

Leona E Ling

Laura Rutitzky

James S Huston

Jonathan C Lansing

James Meador, Iii

Daniel Ortiz

Manuel L Penichet

Jay Duffner

Beatrice Leveugle

Jose A Rodriguez

Gustavo Helguera

Dean L Mann

Lynn Zhang

Chia Lin Chu

Tracy R Daniels

Richard Baum

He Zhou

Zoya Galcheva-Gargova

The present invention relates to methods of using biologically active Fc domain-containing therapeutic constructs (Fc constructs) to induce immune cell activation of the immune response in a subject, and for example, to treat diseases such as cancers and infections in a subject. Such Fc constructs may include 5 or more Fc domains.

Methods related to engineered Fc constructs

Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.

Sialylated glycoproteins

The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.

Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (&#x3b5;) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

IgE antibodies for the treatment of cancer

Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.

Combination therapy for treating disease

The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.

Reagents and methods for inducing an immune response to prostate specific antigen

The invention is therapeutic methods and compositions that alter the immunogenicity of the host.

Therapeutic compositions that alter the immune response

Disclosed are methods and compositions for use in immunotherapy. These methods and compositions are particularly useful for exploiting dendritic cells to present an antigen to a patient, particularly where the patient has a disease associated with the antigen. The invention provides methods for treating a patient having a disease associated with an antigen. The methods according to the invention comprise combining ex vivo an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen, wherein the patient receives a therapeutic benefit.

Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells

Growing community of inventors

Arlington, MA, United States of America

Birgit Corinna Schultes